Eli Lilly's (LLY) Retatrutide demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of Type 2 Diabetes
- Retatrutide lowered A1C by an average of 1.7-2.0% at 40 weeks.
- Participants showed weight loss of up to 16.8%.
Context
Eli Lilly's successful phase 3 trial results for Retatrutide highlight its potential as a competitive treatment for Type 2 Diabetes, with significant improvements in key health metrics like A1C and weight loss. This could enhance Eli Lilly's market positioning within the pharmaceuticals sector, potentially driving interest from investors and impacting earnings forecasts positively, especially in light of the growing diabetes treatment market.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES